

CSL
2023 Research Acceleration Initiative

September 2022

Dr Marco Cavallari
Manager, Research Innovation

Legal Notice

The information provided in this document is provided “as is” without warranty of any kind; either express or implied, and is intended for informational purposes only. The information contained herein is subject to change at any time without notice.

In no event shall CSL Limited be liable for any direct, indirect, special or consequential damages or any damages whatsoever resulting from loss of use, data, or profits arising out of or in connection with the use of this information.

AGENDA

Overview of CSL

Areas of interest for collaboration

CSL Research Acceleration Initiative

Benefits of collaborating with CSL

CSL's core Therapeutic Areas

Questions

Overview of CSL

Our Businesses

CSL Behring

Biotherapies & Rare Disease

CSL Plasma

Plasma Donation

CSL Seqirus

Vaccines

CSL Vifor

Iron Deficiency & Nephrology*

Driven by Our Promise

* CSL will follow the required legal processes of formally changing the names for Vifor Pharma and Seqirus entities in due course.

CSL at a Glance

40+

Countries of operations around the world

US$10.6

Billion in annual revenue

US$4.6

Billion in R&D investments in the last 5 years to advance product pipeline

30,000+

Employees around the world

2000+

R&D employees

330+

Plasma collection centres across China, Europe and North America

Our Locations



Top 25 Biotech Companies of 2022

GEN Genetic Engineering & Biotechnology News

Rank	Company	Ticker Symbol	Market Cap (US$ Billion)
1	Novo Nordisk	NOVO-B (CPH)	236.0
2	Thermo Fisher Scientific	TMO (NASD)	213.4
3	Amgen	AMGN (NASD)	130.8
4	**CSL Ltd**	**CSL (ASX)**	**92.2 B**
5	Gilead Sciences Inc	GILD (NASD)	77.6
6	Regeneron Pharmaceuticals Inc	REGN (NASD)	67.4
7	Vertex Pharmaceuticals	VRTX (NASD)	61.5
8	Moderna	MRNA (NASD)	58.7
9	Chugai Pharmaceutical	4519 (JPX)	52.6
10	Illumina	ILMN (NASD)	50.9
11	Lonza	LONN (SWX)	49.2
12	WuXi AppTec	603259 (SHSE)	47.9
13	Samsung Biologics	207940 (KRX)	42.2
14	Agilent Technologies	A (NYSE)	40.3
15	Jiangsu Hengrui Medicine Co Ltd	600276 (SHSE)	40.1
16	BioNTech SE	BNTX (NASD)	33.4
17	WuXi Biologics	2269 (HKG)	33.3
18	Biogen	BIIB (NASD)	30.8
19	Sun Pharmaceutical Industries	SUNPHARMA (NSE)	26.1
20	Seagan	SGEN (NASD)	23.9

https://www.genengnews.com/a-lists/top-25-biotech-companies-of-2022

Research Acceleration Initiative

CSL's Research Acceleration Initiative

Objective: to build relationships with entrepreneurial researchers and fastrack discovery of innovative medicines that address unmet needs

Focus on early stage projects in specific areas aligned with CSL's Therapeutic Areas

Why? Early collaborations with high quality academic partners are key to building a sustainable pipeline

CSL has a strong interest in supporting local medical research efforts and strengthening POC capability in the countries in which we work

- ✓ Successful applicants receive up to EUR 170k p.a. for up to 2 years
- ✓ CSL scientific champions assigned to each project to provide expert, industry guidance

CSL 2023 Research Acceleration Initiative Process



No obligation for registered organisations to submit applications

No limitation on number of abstracts each registered organisation can submit

Agreement Guidance

Separate collaboration agreements will be negotiated for each project which reflect the nature of the project, nature of funding and support, and the contributions of both parties

Under these negotiated agreements, CSL will be granted certain rights of interest to the program results for further R&D and/or commercialisation

Collaboration agreements will typically include the following terms (although CSL may propose other conditions depending on the nature of the project):

- *Research organisation will own results arising under the project*
  - CSL would typically own any results which relate to proprietary CSL products or materials if they are contributed to the project
  - The RAI is designed to accelerate the translation of novel discoveries made by research scientists – for proposals outside this scope, we may propose that projects be progressed outside the RAI
- *CSL will be granted an exclusive option to negotiate an exclusive, worldwide licence*
- *CSL supports publication of research outcomes*

Further details on agreement terms can be provided on request

Eligibility

To be eligible to apply, researchers/clinicians must satisfy the following 2 conditions:

1. Be employed by a research organization registered to participate in the 2023 Research Acceleration Initiative

2. Submit a 300 word online abstract that is aligned with CSL's Therapeutic Areas and scientific Platforms:



Specific indications of focus within each TA will be provided ahead of the scientific call

Abstract submission via online portal

Step 1/2 - Lead Investigator Information

Fields with * are mandatory

First Name *

Salutation

Last Name *

Job Title *

Organization *

Phone

Email *

Confirm Email *

Address

City

Zip/Postcode

Country *

CONTINUE

Step 2/2 - Describe your opportunity and confirm submission

Please describe and categorize your opportunity.

Fields with * are mandatory

Proposal Title *

Therapeutic Area *

- Cardiovascular & Metabolic
- Hematology
- Immunology
- Respiratory
- Transplant
- Not specific to a Therapeutic Area (e.g. platform technology)

Indications *

Modality *

- Plasma
- Recombinant (incl. antibodies)
- Gene therapy
- Cell therapy
- Peptide
- Extracellular vesicles
- Oligonucleotide (siRNA, asRNA, ncRNA)
- Small molecule
- Other modality

Project Description (max. 300 words) *

Example of what to include in Project Description: "We have discovered a novel target expressed on X cells. We have generated data in X assay(s) and/or X model(s). We have shown the mechanism of action is mediated via X pathway(s). Inhibition of this target could be used to treat X indication(s). This novel strategy could address an important unmet need for patients and be superior to standard of care and other therapeutics in development for reasons X, X and X."

I have read the privacy policy and agree with it. Read more... *

I hereby confirm that my submission does not contain any confidential information. *

I'm not a robot

reCAPTCHA

Privacy - Terms

BACK SUBMIT

Submission T&Cs on last slide

What is involved for participating research organisations?

Abstract submission

- Internal promotion of initiative (*CSL to provide flyer)*
- Promotion of CSL information sessions/webinars for interested researchers
- Provide abstract submission portal link to researchers
- Discuss proposals with interested scientists ahead of 300 word abstract submission deadline

Full Proposal

- Support shortlisted researchers with preparation of full proposal via CSL RAI application form
- Ensure no disclosure of confidential information prior to submission of applications to CSL

RAI Finalists

- Facilitation of CDA
- Assist with scheduling of confidential presentations to CSL

Successful applicants

- Contract negotiation
- Preparation of detailed research plan and budget in partnership with CSL

Connect CSL with the appropriate internal contact(s) for each stage of the process

CSL's core Therapeutic Areas



CSL's Core Therapeutic Areas & Platforms



R&D Portfolio – FY22

Immunology | Hematology | Respiratory | Cardiovascular & Metabolic | Vifor Pharma
Transplant | Influenza Vaccines | Outlicensed Programs | Partnered Projects

Phase I

CSL324
Anti-G-CSFR mAb (HS)

CSL730
rFc Multimer

CSL889
Hemopexin (SCD)

CSL787
Nebulised Ig

CSL311
Anti-Beta Common mAb

ASLAN004
Anti-IL-13R mAb (AD)

INS-3001
Oral calcification inhibitor
(PAD, aortic valve stenosis)

Phase II

HIZENTRA®
(SSc)

Garadacimab
Anti-FXIIa mAb (ILD/IPF)

CSL346
Anti-VEGF-B mAb
(DKD)

Adjuvanted Cell Culture Influenza Vaccine (aQIVc)

Mavrilimumab
Anti-GM-CSFR mAb
(GCA, COVID)

VIT-2763
Oral ferroportin inhibitor
(Sickle cell disease)

VIT-2763
Oral ferroportin inhibitor
(Beta-thalassemia)

Phase III

Garadacimab
Anti-FXIIa mAb (HAE)

HIZENTRA®
(DM)

EtranaDez
Etranacogene dezaparvovec
(Hem B)

KCENTRA®
4F-PCC (Trauma)

Sparsentan[1]
Dual ET_A & AT_1 antagonist
(FSGS)

Sparsentan[1]
Dual ET_A & AT_1 antagonist
(IgA Nephropathy)

CSL112
apoA-I (AMI)

Clazakizumab
Anti-IL-6 mAb (AMR)

CSL964
Alpha-1 Antitrypsin
(Treatment of GvHD)

CSL964
Alpha 1 Antitrypsin
(Prevention of GvHD)

SNF-472
Calcification inhibitor
(CUA-ESRD)

SNF-472
Calcification inhibitor
(PAD-ESRD)

1 Licensed from Travere Therapeutics, Inc.
2 Licensed from Cara Therapeutics, Inc.
3 Licensed from ChemoCentryx, Inc.
4 Licensed from OPKO Health, Inc.

Registration/Post-Registration

HAEGARDA®
(HAE)

HIZENTRA®
(SCIg) 20% Liquid

PRIVIGEN®
(IVIg) 10% Liquid

AFSTYLA®
rFVIII (Hem A)

IDELVION®
rFIX-FP (Hem B)

ZEMAIRA®/RESPREEZA®
Alpha-1 Antitrypsin

FOCLIVIA®/FOCETRIA
Adjuvanted Egg-based
Influenza A (H5N1) Vaccine

VELTASSA
Oral potassium binder
(Hyperkalemia)

KORSUVA/KAPRUVIA[2]
Kappa-opioid rec. agonist
(CKD-aP)

AUDENZ™
Adjuvanted Monovalent
Influenza A (H5N1) Vaccine

AFLURIA® QUAD
Egg-based Influenza Vaccine

FLUAD® Trivalent
Adjuvanted Influenza Vaccine

FLUAD® Quadrivalent
Adjuvanted Influenza Vaccine

FLUCELVAX® Quadrivalent
Cell-based Influenza Vaccine

PANVAX®
Egg-based Influenza Vaccine

TRAVENOS®[3]
Oral C5a receptor
(ANCA associated vasculitis)

RAYALDEE®[4]
Oral calcifediol
(Sec. hyperparathyroidism)

* Indicative of combined CSL/Vifor FY22 R&D portfolio assuming completion of acquisition.

Vadadustat licensed from Akebia Therapeutics, Inc.; Status pending - Complete Response Letter (CRL) received from FDA due to safety concerns.

Formal integration of Vifor's R&D programs into CSL's R&D portfolio will be subject to CSL's standard R&D portfolio review, management and integration processes.

Product and pipeline highlights

Privigen® (10% intravenous Ig)
Primary immunodeficiencies (PID), Secondary Immune Deficiency (SID)*, Chronic inflammatory demyelinating polyneuropathy (CIDP)

Hizentra® (20% subcutaneous Ig)
PID, CIDP, SID*
Dermatomyositis (DM), Ph III
Systemic sclerosis (SSc), Ph II

Haegarda® (C1 Esterase Inhibitor)
Hereditary angioedema

Garadacimab (Anti-FXIIa mAb)
Hereditary angioedema, Ph III

CSL324 (Anti-G-CSFR mAb)
Hidradenitis suppurativa (HS), Ph I

CSL730 (Recombinant Trivalent Human IgG1 Fc Multimer), Ph I

Gene Therapy Treatments
PID, Research

Idelvion® (Recombinant FIX-FP)
Hemophilia B

Afstyla® (Recombinant FVIII)
Hemophilia A

Kcentra® (Prothrombin complex concentrate)
Urgent warfarin reversal

Etranacogene dezaparvovec
(AAV FIX gene therapy)
Hemophilia B, Ph III

CSL889 (Hemopexin)
Sickle cell disease, Ph I

CSL888 (Haptoglobin)
Sub-arachnoid hemorrhage, preclinical development

ZEMAIRA®/RESPREEZA®
(Alpha 1 Antitrypsin)

Garadacimab (Anti-FXIIa mAb)
Idiopathic Pulmonary Fibrosis, Ph IIa

CSL311 (Anti-β-common mAb)
Airways inflammation, Ph I

CSL787 (Nebulised Ig)
Respiratory infections, Ph I



CSL112 (ApoA-1)
Acute coronary syndrome, Ph III

CSL346 (Anti-VEGFB mAb)
Diabetic kidney disease, Ph II

FLUAD Quadrivalent
Adjuvanted Influenza Vaccine

FLUCELVAX Quadrivalent
Cell-based Influenza Vaccine

Adjuvanted Cell Culture Influenza Vaccine (aQIVc), phase II

sa-mRNA Influenza Vaccine, PC

CSL964 (Alpha 1 Antitrypsin)
Graft versus host disease, Ph III

Clazakizumab (Anti-IL-6 mAb)
Antibody mediated rejection, Ph III

CSL040 (Novel Complement Inhibitor), PC

*ex-USA

Our full pipeline can be viewed here

Areas of interest for collaboration



Immunology

Core interests for external collaboration

Immune deficiencies

Primary immune deficiency gene therapy and targets

Autoimmune diseases

e.g. Primary Sjögren's syndrome, systemic sclerosis, inflammatory idiopathic myopathies incl. dermatomyositis, autoimmune blistering diseases

Therapeutic strategies for autoimmune diseases

- Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF-family members
- B cell depletion / regulation strategies

Alternatives to plasma-derived Ig / Recombinant IVIg

Hematology

Core interests for external collaboration

Hemorrhagic and acute ischemic stroke

- Novel biologic targets / therapeutics or strategies to understand pathomechanisms
- Biomarker / Omics approaches for patient stratification and drug discovery

Acute thrombosis (venous and arterial thrombosis)

Novel therapies / approaches for targeted fibrinolysis / thrombolysis with increased efficacy and safety

Sickle cell disease

Prophylactic therapies to reduce vaso-occlusive crises and chronic vasculopathy

Respiratory

Core interests for external collaboration

Asthma
(severe, uncontrolled)

Chronic obstructive pulmonary disease
(exacerbations)

Non-cystic fibrosis bronchiectasis

Interstitial lung diseases
(progressive fibrosing)

Community acquired pneumonia (CAP)-associated complications
(acute respiratory distress syndrome, sepsis, acute kidney injury)



Cardiovascular and Metabolic

Core interests for external collaboration

Myocarditis

Dilated cardiomyopathy
Inflammatory etiologies

Severe forms of atherosclerosis
Inflammatory targets/candidates

Rare lipid disorders
(e.g. homozygous familial hypercholesterolemia)

Transplant

Core interests for external collaboration

Chronic lung allograft dysfunction
Including prevention, antibody-mediated rejection, tolerance, immunomodulation, biomarkers, animal models

Hematopoietic stem cell transplant (HSCT)
Treatment and prevention of acute and chronic GvHD, tolerance, immunomodulation, improving efficacy / safety of HSCT

Cardiovascular allograft vasculopathy
Treatment and animal models

Ischemia reperfusion injury
Prevention



Vaccines

Core interests for external collaboration

mRNA and lipid nanoparticle platform
Innovative research addressing improved delivery, formulation, stabilization (5°C / room temperature), shelf-life extension and manufacturing technologies

Influenza virus antigen purity and yield enhancement
Innovative research with potential to impact yield and purity of influenza virus HA antigen produced in MDCK cell culture

Proven adjuvant technology
Partnerships with our proprietary adjuvant MF59®

CSL's Areas of Interest for Collaborations

- *In vivo* kill switch or suicide switch
- Modulation of transgene expression *in vivo*
- Novel methods to select gene modified HSCs
- Novel therapeutic gene therapy targets aligned with CSL's Therapeutic Areas
- Non-viral *in vivo* delivery of RNPs
- Alternative mRNA delivery methods

- Oral delivery of biologics
- Protein purification technologies
- Bioprocess improvements
- MDCK cell culture yield improvements



- Antibodies
- Protein therapeutics
- LV gene therapies
- Cell therapies
- Structural vaccinology

Areas <u>not</u> of interest

- *Oncology (including hematological malignancies)*
- *Medical devices or diagnostics*
- *Small molecule approaches*

Benefits of collaborating with CSL



Capabilities from Discovery to Patients

Target Discovery

Translational Medicine & Data Science

Phase I / II Manufacturing

Patients

THERAPEUTIC PLATFORMS **CLINICAL STUDIES**



Animal Models of Disease

Toxicology & Product Development

Phase III / Launch Manufacturing

Benefits of collaborating with CSL

Global capabilities on your doorstep

Work with one of the world's leading biotech companies

Funding for successful proposals

Access to commercial, R&D, clinical, intellectual property, marketing and manufacturing expertise

Accelerate translation of your research to deliver new **therapies**

34 new partnerships established via the Research Acceleration Initiative since 2019

>200 active **Research collaborations**

170+ scientific papers published with our collaborators since 2020

Checklist for 2023 Research Acceleration Initiative



- Register your research organisation by 11th Dec 2022 by emailing RAI@cslbehring.com (NB: 2022 participants are automatically re-enrolled)
- Update your organization's primary contact details if required
- CSL will provide flyer with primary contact details for promotion within your research organizations
- CSL will provide the link to the online abstract submission portal
- CSL will provide you with invitations to information webinars to share with interested researchers – webinars will be held in Feb 2023
- Online portal opens for abstract submissions by researchers on 3rd Jan 2023 and closes on 23rd Feb 2023

Questions

THANK YOU

Dr Marco Cavallari
Manager, Research Innovation

marco.cavallari@cslbehring.com

RAI@cslbehring.com

csl.com/csl-rai



Terms and Conditions for Research Acceleration Initiative Portal ("RAI Portal")

1. This RAI Portal is an online portal operated by CSL Innovation Pty Ltd ("CSL") for the purpose of allowing individuals to submit scientific proposals for consideration by CSL for its Research Acceleration Initiative program. By using this website and the RAI Portal, and by providing your submission and personal information to CSL, you are agreeing to abide by these terms and conditions.

2. You acknowledge and agree that CSL has no obligations of confidentiality or non-use in relation to the submission provided. You warrant that your submission does not contain confidential information of any kind. Further, you acknowledge that notwithstanding the existence of any confidentiality agreements previously entered into between you and CSL, the terms of such agreements will not apply with respect to any information submitted by you through the RAI Portal.

3. You further represent and warrant that:

- a. you have the right and authorisation (including where relevant after consultation with all relevant commercialisation or technology transfer offices) to submit an application to the RAI Portal and to accept the terms and conditions set out herein;
- b. you are an employee or are otherwise affiliated with a registered organisation authorised by CSL to submit an application to the RAI Portal; and
- c. to the best of your knowledge and without making any further enquiries, the information provided in your submission (and CSL's use of that information in connection with the Research Acceleration Initiative program) shall not infringe on the intellectual property rights of any third party, including your current or former employer, university, public research institute or other registered organisation.

4. CSL may disclose personal information collected in connection with your use of this website or the RAI Portal to your employer, university, public research institute or other registered organisation (if applicable) as at the time your application was submitted, solely for the purpose of reviewing and determining your application. CSL will ensure that any personal information collected, used or disclosed in connection with your use of this website or the RAI Portal is handled in accordance with all relevant privacy legislation and with CSL's privacy policy, a copy of which is available at https://www.csl.com/privacy-policy.

5. CSL is under no obligation to respond to any individual application submitted to the RAI Portal, and may in its sole discretion choose not to progress an application further for any reason without any further communication with you.